by Roger Longman
The industry is now well past the time when licensing was a corporate backstop, seen as a mere supplement to...
The pharmaceutical industry is well past the time when licensing was seen as merely a supplement to the internal R&D program. Now, it often plays a more important role than the company's internal R&D. As dealmaking becomes a bigger part of the overall pipeline building program, investors will require greater clarity from companies who now can bury external dealmaking costs in one-time write-offs or aggregated clash flow numbers.
by Roger Longman
The industry is now well past the time when licensing was a corporate backstop, seen as a mere supplement to...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.